We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

PerkinElmer to Acquire Oxford Immunotec Global PLC

By LabMedica International staff writers
Posted on 08 Jan 2021
Print article
Illustration
Illustration
PerkinElmer, Inc. (Waltham, MA; USA) has reached an agreement to acquire Oxford Immunotec Ltd. (Abingdon, UK) that will allow the company to grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection.

The deal will enable PerkinElmer to combine its channel expertise and leading workflow and testing capabilities with Oxford Immunotec’s leading proficiencies in T cell immunology with its proprietary test kits for latent tuberculosis. Oxford Immunotec is the only company in the world offering regulated ELISPOT assays for T cell measurement, with approval around the globe. The company’s T-SPOT.TB test is used for diagnosing infection with tuberculosis and it has manufactured in excess of 20 million clinical T cell tests for TB infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the US, where it has received pre-market approval from the FDA, Europe, where it has obtained a CE mark, as well as Japan and China.

“Tuberculosis remains one of the leading infectious causes of death, with close to one quarter of the world’s population infected,” said Prahlad Singh, PhD, President and Chief Executive Officer of PerkinElmer. “We believe Oxford Immunotec’s diagnostic testing solution plays an important role in slowing the spread and saving lives. Oxford Immunotec’s highly sensitive test and their team’s passion for solving complex health issues make it a natural fit with PerkinElmer’s mission and together, we believe will accelerate development of robust solutions to help detect infectious disease.”

“We are delighted to be joining the PerkinElmer family. We believe this transaction is great for our shareholders, our employees and our customers,” said Peter Wrighton-Smith, PhD, Chief Executive Officer of Oxford Immunotec. “Access to PerkinElmer’s global reach and automation experience will enable us to accelerate our growth journey and make a growing impact in the field of infectious disease.”




New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
Gold Supplier
SARS-CoV-2 Neutralizing Antibody Test Kit (Fluorescence Immunoassay)
SARS-CoV-2 Neutralizing Antibody Test Kit (Fluorescence Immunoassay)
New
SARS-CoV-2 Real-Time RT-PCR Test
GB SARS-CoV-2 Real-Time RT-PCR [E/N/ORF1ab (RdRp)]
New
SARS-CoV-2 IgM ELISA
SARS-CoV-2 IgM ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.